# ACTION-1 (NCT05477576)

> Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05477576
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: RayzeBio, Inc.
- Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET
- Interventions: RYZ101; Everolimus; Sunitinib; Octreotide; Lanreotide
- Enrollment: 343
- Primary outcome: Phase 1b: RP3D
- Primary outcome: Phase 3: PFS as determined by BICR

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=action-1-nct05477576